Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations
Christian F. Singer(Comprehensive Cancer Center Vienna), D. Gareth Evans(Manchester Academic Health Science Centre), Mateja Krajc(Institute of Oncology Ljubljana), Eli Marie Grindedal(Oslo University Hospital), Kamil Pohlodek(Comenius University Bratislava), Manuel R. Teixeira(Instituto Português de Oncologia Francisco Gentil), Bella Kaufman(NYU Langone Health), Maria Elisabetta Filieri, Suzette Delaloge(Institut Gustave Roussy), Judith Balmañà(Vall d'Hebron Hospital Universitari), Anna-Marie Gerdes(Rigshospitalet), Niklas Loman(Lund University), Oskar Johansson(Reykjavík University), Nicole Bürki(University Hospital of Basel), Edith Oláh(National Institute of Oncology), Kerstin Rhiem(University Hospital Cologne), Shani Paluch–Shimon(Hebrew University of Jerusalem), Sileni Han(Universitair Ziekenhuis Leuven), Natalija Dedić Plavetić(University Hospital Centre Zagreb)
Cited by 37
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k